ArticleAfrican journal of infectious diseases2025
EFFECT OF DIURNAL INTERMITTENT FASTING (DIF) ON ANTIOXIDANT AND PRO INFLAMMATORY MEDIATORS ACTIVITY IN MALE RAT MODEL OF TYPE 2 DIABETES MELLITUS.
Article in African journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by persistent hyperglycemia, oxidative stress, and systemic inflammation. Diurnal intermittent fasting (DIF), a fasting pattern synchronized with circadian rhythms, has been proposed as a potential strategy to alleviate metabolic disturbances, but evidence from controlled animal studies remains limited. Materials and Methods: This experimental study employed a post-test-only control group design using thirty-six male Wistar rats. T2DM was induced by streptozotocin (65 mg/kg) and nicotinamide (230 mg/kg). Animals were randomized into four groups: diabetic control (G1), and three DIF-treated groups fasting two (G2), three (G3), and six (G4) days per week. Blood glucose was measured weekly. On day 28, serum levels of superoxide dismutase (SOD) and interleukin-6 (IL-6) were analyzed using enzyme-linked immunosorbent assay (ELISA). Results: DIF significantly reduced blood glucose levels in all intervention groups compared to the control (p < 0.05). The G4 group showed the highest SOD activity and the greatest IL-6 reduction (p < 0.05). However, there was no significant glucose difference between G3 and G4, suggesting a plateau in glycemic improvement. Conclusion: DIF improves glycemic control, enhances antioxidant defense through increased SOD activity, and reduces systemic inflammation via IL-6 suppression in a T2DM rat model. These findings support the potential of DIF as a complementary therapeutic approach for T2DM, although further research is needed to determine the optimal fasting regimen and its applicability in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.